Phase 2 Genetic Clinical Trials
13 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–13 of 13 trials
Recruiting
Phase 2Phase 3
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Symptomatic Genetic Dilated Cardiomyopathy
Kardigan, Inc.332 enrolled33 locationsNCT07210723
Recruiting
Phase 2
Effects of Treatments on Atopic Dermatitis
DermatitisEczemaSkin Diseases, Genetic
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)130 enrolled1 locationNCT01631617
Recruiting
Phase 2
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting
Phase 2
Microbiome and Association With Implant Infections
Breast CancerBreast Cancer FemaleGenetic Predisposition to Disease
University of California, San Francisco200 enrolled1 locationNCT05020574
Recruiting
Phase 1Phase 2
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Plasma Cell LeukemiaUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High Risk+4 more
Institute of Hematology & Blood Diseases Hospital, China50 enrolled1 locationNCT07109323
Recruiting
Phase 1Phase 2
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316
Recruiting
Phase 2
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
Genetic DiseaseIdiopathic Infantile Hypercalcaemia - Severe FormHypercalcemia, Idiopathic, of Infancy+3 more
Children's Hospital of Philadelphia60 enrolled1 locationNCT03301038
Recruiting
Phase 2
Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
Genetic DiseaseFetal HemoglobinThalassemia Major
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan54 enrolled1 locationNCT06490627
Recruiting
Phase 2
Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial
ImmunosenescenceEpigenetic Aging
Intervene Immune, Inc.85 enrolled1 locationNCT04375657
Recruiting
Phase 2
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Peripheral T Cell LymphomaEpigenetic Repression
Institute of Hematology & Blood Diseases Hospital, China37 enrolled1 locationNCT05958719
Recruiting
Phase 2
PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)
Coronary DiseaseBleedingCoronary Artery Disease+5 more
Federal University of São Paulo120 enrolled1 locationNCT06542393
Recruiting
Phase 2
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+4 more
Australasian Leukaemia and Lymphoma Group39 enrolled1 locationNCT06287398
Completed
Phase 2
The effect of the antiviral drug, Peg-interferon, in patients with relapsed haematological malignancy after initial sibling or volunteer unrelated allogeneic haematopoietic progenitor cell transplantation (HPCT)
Haematological relapse (more than or equal to 5 percent blasts) or non-Haematological relapse (molecular, cytogenetic or flow cytometry only) after initial sibling or volunteer unrelated allogeneic HPCT.
Royal Brisbane and Womens Hospital30 enrolled1 locationACTRN12612000728831